Glycemic Control and Cardiovascular Risk in Type 2 Diabetics Using Metformin vs. Combination Therapy

Sehrish Jabeen; Anam; Fatima Abass; Syeda Aisha; Saba Khalid

doi:10.62497/irabcs.141

Authors

Sehrish Jabeen Department of Pharmacy, Abasyn University, Peshawar, Pakistan Author
Anam Hazrat Khadija Hospital, Latifabad Hyderabad, Pakistan Author
Fatima Abass Internal Medicine, Lahore General Hospital, Pakistan Author
Syeda Aisha Institute of Biotechnology & Genetic Engineering, University of Sindh, Jamshoro, Pakistan Author
Saba Khalid Internal Medicine, Jinnah Hospital Lahore, Pakistan Author

DOI:

https://doi.org/10.62497/irabcs.141

Keywords:

Type 2 diabetes mellitus, metformin, combination therapy, glycemic control, cardiovascular risk, HbA1c

Abstract

Introduction: Type 2 diabetes mellitus (T2DM) is a growing public health concern worldwide. While metformin is the first-line therapy, many patients require additional oral antidiabetic drugs (OADs) to achieve glycemic targets.

Objective: To determine which is better at controlling blood sugar and lowering the risk of heart disease in people with type 2 diabetes: metformin monotherapy or combination treatment.

Materials and Methods: The descriptive, cross-sectional research was conducted at the Department of Endocrinology at Jinnah Hospital in Lahore between February 2023 and January 2024. A total of 132 T2DM patients were enrolled using convenience sampling and divided into two groups: Group A (metformin only; n=62) and Group B (metformin plus OADs; n=70). Fasting blood glucose, HbA1c, blood pressure, and lipid profile were assessed. Independent samples t-tests were used to compare means between groups, with p<0.05 considered statistically significant.

Results: Group B patients had far better blood sugar management than Group A patients. Their fasting blood sugar levels were 134.6 mg/dL compared to 144.2 mg/dL (p = 0.047), and their mean HbA1c levels were 7.36% compared to 7.94% (p = 0.002). Group B included 36 patients (51.43%) who were able to regulate their blood sugar levels (HbA1c <7%), whereas Group A had 18 patients (29.03%) who were able to do the same. In Group A, 39 patients (62.90%) and in Group B, 34 patients (48.57%) had dyslipidemia. There were 28 patients (45.16%) with high blood pressure in Group A and 29 patients (41.43%) in Group B.

Conclusion: Combination therapy with metformin and other OADs was associated with better glycemic control compared to metformin monotherapy. However, no significant reduction in cardiovascular risk factors was observed. Further longitudinal studies are needed to explore long-term outcomes and safety, including hypoglycemia risk.

Downloads

Download data is not yet available.

References

Nolan CJ, Prentki M. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift. Diabetes and Vascular Disease Research. 2019 Mar;16(2):118-27. https://doi.org/10.1177/1479164119827611

Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. The American journal of cardiology. 2002 Sep 5;90(5):3-10. https://doi.org/10.1016/S0002-9149(02)02553-5

Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature reviews endocrinology. 2018 Feb;14(2):88-98. https://doi.org/10.1038/nrendo.2017.151.

Roman G, Stoian AP. Cardiovascular risk/disease in type 2 diabetes mellitus. InType 2 Diabetes-From Pathophysiology to Cyber Systems 2021 Apr 20. IntechOpen. DOI: 10.5772/intechopen.97422.

Kaur, R., Kaur, M. & Singh, J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol 17, 121 (2018). https://doi.org/10.1186/s12933-018-0763-3.

Stolar M. Glycemic control and complications in type 2 diabetes mellitus. The American journal of medicine. 2010 Mar 1;123(3):S3-11. https://doi.org/10.1016/j.amjmed.2009.12.004.

Ahmad E, Sargeant JA, Zaccardi F, Khunti K, Webb DR, Davies MJ. Where does metformin stand in modern day management of type 2 diabetes?. Pharmaceuticals. 2020 Nov 27;13(12):427. https://doi.org/10.3390/ph13120427.

Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. The American journal of medicine. 1997 Jan 1;102(1):99-110. https://doi.org/10.1016/S0002-9343(96)00353-1

El Mouhayyar C, Riachy R, Khalil AB, Eid A, Azar S. SGLT2 inhibitors, GLP‐1 agonists, and DPP‐4 inhibitors in diabetes and microvascular complications: a review. International journal of endocrinology. 2020;2020(1):1762164. https://doi.org/10.1155/2020/1762164.

Vesa CM, Popa L, Popa AR, Rus M, Zaha AA, Bungau S, Tit DM, Corb Aron RA, Zaha DC. Current data regarding the relationship between type 2 diabetes mellitus and cardiovascular risk factors. Diagnostics. 2020 May 16;10(5):314. https://doi.org/10.3390/diagnostics10050314.

Rani MU, Vaddepalli S, Singh D, Nagamani PS. Glycemic Control And Cardiovascular Risk In Patients On Dual Therapy With Metformin And Ace Inhibitors: A Longitudinal Observational Study. Int J Acad Med Pharm. 2023;5(5):295-8. DOI: 10.47009/jamp.2023.5.5.58.

Lin YY, Weng SF, Hsu CH, Huang CL, Lin YP, Yeh MC, Han AY, Hsieh YS. Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus. Frontiers in Medicine. 2022 Oct 14;9:995944. https://doi.org/10.3389/fmed.2022.995944.

Ou SM, Shih CJ, Chao PW, Chu H, Kuo SC, Lee YJ, Wang SJ, Yang CY, Lin CC, Chen TJ, Tarng DC. Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Annals of internal medicine. 2015 Nov 3;163(9):663-72. https://doi.org/10.7326/M15-0308.

Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. Jama. 2000 Apr 5;283(13):1695-702. doi:10.1001/jama.283.13.1695.

Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Esposito K. Glycemic control, preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with meta‐analysis of cardiovascular outcome trials and intensive glucose control trials. Journal of the American Heart Association. 2019 Jun 18;8(12):e012356. https://doi.org/10.1161/JAHA.119.012356.

Jadzinsky M, Pfützner A, Paz‐Pacheco E, Xu Z, Allen E, Chen R, CV181‐039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity and Metabolism. 2009 Jun;11(6):611-22. https://doi.org/10.1111/j.1463-1326.2009.01056.x.

Li, T., Providencia, R., Mu, N. et al. Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 20, 30 (2021). https://doi.org/10.1186/s12933-020-01202-5.